Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
SouthernSun Small Cap Michael W. Cook | “Stepan Company (SCL) was a detractor in the Small Cap strategy in the third quarter. The company continues to execute on its strategy to grow its functional surfactants, which serve the agriculture and oilfield market, as well as its Tier 2 and Tier 3 surfactant volumes, which represents sales to smaller customers formulating specialty products. The second quarter results reflected solid growth in these end markets. However, weakness in the commodity consumer product end markets offset growth in these areas, and overall Surfactant segment volumes were down 1%. In the Polymer segment, volumes were up 7% driven by strength in the North American and European rigid polyols end markets despite continued headwinds from a weak macro environment and tariff uncertainty. As of the end of the second quarter, SCL generated $197 million in trailing 12-month EBITDA, and management makes a strong case that the business should generate $60 million quarterly as some market headwinds abate and the recently installed new alkoxylation capacity in Pasadena, TX, comes online later this year. SCL ended the second quarter with net debt to trailing 12-months EBITDA of 2.9x, and we expect this ratio to come down now that the heavy investment period is behind them. Luis Rojo was promoted to the CEO position in October 2024 after serving as CFO for 6 years, and we have been impressed with his execution of the business strategy so far. SCL is recognized as an industry leader in formulating new products and applications for its surfactants and polymers, and we believe the company has developed valuable, long-term relationships with customers that will continue to generate steady cash flow. BSD Analysis: SCL offers a blend of specialty growth and cyclical recovery. Capacity expansion at Pasadena will enhance efficiency, while mix shift toward functional surfactants supports margin stability. Deleveraging trajectory improves financial flexibility. Trading at reasonable EV/EBITDA with solid customer stickiness, SCL looks positioned for moderate re-rating as macro headwinds fade.” | BEAR | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
